Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115381) titled 'Study on the Role and Mechanism of Indirubin Nanoparticles in Inflammatory Bowel Disease' on Dec. 25, 2025.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Taizhou First People's Hospital
Condition:
Inflammatory bowel disease (ulcerative colitis and Crohn's disease
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-01
Target Sample Size: Inflammatory Bowel disease Observation Group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=293623
Disclaimer: Curated by HT Syndication....